Common Side Effects Patients Report
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, carries risks of upper respiratory infections, diarrhea, and nasopharyngitis, affecting 10-20% of users in clinical trials. Injection site reactions occur in about 10% of patients.[1]
Serious Complications and Warnings
Black box warnings highlight increased risk of serious infections like tuberculosis (TB) reactivation—screening is required before starting. Other reports include inflammatory bowel disease (IBD) flares, with Crohn's disease worsening in 1-2% of cases, and rare cases of hypersensitivity reactions or anaphylaxis. FDA post-marketing data notes severe fungal infections and neutropenia.[2][3]
What Infections Are Most Reported?
Patients frequently report candidiasis (oral or esophageal thrush) due to immune suppression, with rates up to 3% in trials. Urinary tract infections and herpes zoster (shingles) also appear in real-world data, sometimes requiring hospitalization.[1][4]
Long-Term Risks and Monitoring
Over 5 years, malignancy risk remains low but monitored; no strong causal link established. Liver enzyme elevations occur in <1%, and some report new-onset IBD. Regular blood tests and TB checks are standard.[2]
Patient Experiences from Forums and Reviews
On platforms like Drugs.com and Reddit, users cite fatigue, headaches, and joint pain flares early on. Severe cases include sepsis or pneumonia in immunocompromised patients. A 2023 study found 15% discontinuation due to adverse events.[5]
How Does This Compare to Other Biologics?
Versus Humira or Stelara, Cosentyx has similar infection rates but higher IBD risk, leading to caution in gut disorder patients. Efficacy often outweighs risks for moderate-severe cases.[1][6]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: DrugPatentWatch.com - Cosentyx Safety Data
[4]: ClinicalTrials.gov - Secukinumab Adverse Events
[5]: JAMA Dermatology 2023 Review
[6]: NEJM Comparison Study